Danaher Co. (NYSE:DHR) Shares Acquired by Godsey & Gibb Inc.

Godsey & Gibb Inc. increased its stake in Danaher Co. (NYSE:DHR) by 3.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,492 shares of the conglomerate’s stock after buying an additional 50 shares during the quarter. Godsey & Gibb Inc.’s holdings in Danaher were worth $415,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Oak Thistle LLC acquired a new stake in shares of Danaher in the second quarter valued at about $363,000. Norden Group LLC acquired a new stake in shares of Danaher in the first quarter valued at about $4,151,000. Duality Advisers LP purchased a new position in Danaher in the first quarter valued at about $5,573,000. Investment Research & Advisory Group Inc. purchased a new position in Danaher in the first quarter valued at about $1,186,000. Finally, Diversified Trust Co boosted its holdings in Danaher by 75.4% in the second quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock valued at $1,090,000 after purchasing an additional 1,874 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on DHR. Evercore ISI increased their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stephens began coverage on Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Bank of America increased their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $282.12.

Danaher Stock Up 0.9 %

DHR opened at $274.38 on Monday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The stock has a market cap of $203.23 billion, a P/E ratio of 46.51, a P/E/G ratio of 4.49 and a beta of 0.83. The stock’s 50 day moving average price is $270.72 and its 200 day moving average price is $260.13.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm earned $2.05 EPS. The firm’s revenue was down 2.9% compared to the same quarter last year. As a group, research analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Activity

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.